← Back to Clinical Trials
Recruiting NCT07487155

NCT07487155 Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07487155
Status Recruiting
Phase
Sponsor University Hospital, Brest
Condition Attention Deficit Disorder With Hyperactivity (ADHD)
Study Type INTERVENTIONAL
Enrollment 39 participants
Start Date 2026-08-03
Primary Completion 2028-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Workshop

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 39 participants in total. It began in 2026-08-03 with a primary completion date of 2028-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.

Eligibility Criteria

Inclusion Criteria: * Adult, under the supervision of the justice system or monitored by a correctional facility * Diagnosis of Substance Use Disorder (SUD) * Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) * No objection from the patient * Affiliated with a Social Security system Exclusion Criteria: * Severe or decompensated psychiatric disorders * Severe cognitive impairment * Lack of understanding of the French language * Refusal to participate

Contact & Investigator

Central Contact

Marie BARAIS, MD

✉ marie.barais@gmail.com

📞 +332 98 01 64 02

Principal Investigator

Morgane GUILLOU-LANDREAT, MD

PRINCIPAL INVESTIGATOR

CHU Brest

Frequently Asked Questions

Who can join the NCT07487155 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Attention Deficit Disorder With Hyperactivity (ADHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07487155 currently recruiting?

Yes, NCT07487155 is actively recruiting participants. Contact the research team at marie.barais@gmail.com for enrollment information.

Where is the NCT07487155 trial being conducted?

This trial is being conducted at Brest, France.

Who is sponsoring the NCT07487155 clinical trial?

NCT07487155 is sponsored by University Hospital, Brest. The principal investigator is Morgane GUILLOU-LANDREAT, MD at CHU Brest. The trial plans to enroll 39 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology